Tiedemann Advisors’s Relmada Therapeutics RLMD Stock Holding History

Tiedemann Advisors’s Portfolio RLMD Stock Details RLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$95.1K	Hold	31,715	–	–	﹤0.01%	268
2023 Q2	$78K	Buy	31,715 +1,500	+5%	+$4.15K	﹤0.01%	252
2023 Q1	$68.3K	Buy	30,215 +10,000	+49%	+$34.5K	﹤0.01%	242
2022 Q4	$70.6K	Buy	20,215 +10,000	+98%	+$87.8K	﹤0.01%	234
2022 Q3	$377K	Hold	10,215	–	–	0.02%	169
2022 Q2	$194K	Buy	+10,215	New	+$223K	0.01%	218
2021 Q3	–	Sell	-55,556	Closed	-$1.78M	–	351
2021 Q2	$1.78M	Hold	55,556	–	–	0.07%	117
2021 Q1	$1.96M	Hold	55,556	–	–	0.09%	105
2020 Q4	$1.78M	Sell	55,556 -214,283	-79%	-$7.36M	0.09%	108
2020 Q3	$10.2M	Sell	269,839 -12,753	-5%	-$493K	0.49%	35
2020 Q2	$12.6M	Hold	282,592	–	–	0.67%	27
2020 Q1	$9.64M	Hold	282,592	–	–	0.62%	31
2019 Q4	$11M	Buy	+282,592	New	+$8.59M	0.53%	41

Other funds holding RLMD

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

PCM

Parsons Capital Management Providence, Rhode Island $2.19B AUM 20.87% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Tiedemann Advisors's RLMD Position: Q3 2023 in Review

Tiedemann Advisors held its Relmada Therapeutics (RLMD) position steady in Q3 2023 at 31,715 shares worth $95.1K. The position accounts for ﹤0.01% of the portfolio, ranked #268.

Tiedemann Advisors first reported a position in RLMD in Q4 2019 and has held it in 13 quarters since. The position peaked at $12.6M in Q2 2020. 87 funds tracked by Wall St. Rank hold RLMD as of Q3 2023.

Tiedemann Advisors held 31,715 shares of Relmada Therapeutics worth $95.1K as of Q3 2023.
Tiedemann Advisors left its Relmada Therapeutics share count unchanged in Q3 2023.
Relmada Therapeutics made up ﹤0.01% of Tiedemann Advisors's portfolio in Q3 2023, its #268 holding.
Tiedemann Advisors first reported a position in Relmada Therapeutics in Q4 2019 and has held it in 13 quarters since.
Tiedemann Advisors's Relmada Therapeutics position peaked at $12.6M in Q2 2020.
87 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q3 2023.

Based on Tiedemann Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.